SCHEMBL22494797

SCHEMBL22494797

N#CN[C@H]1CCN(C(=O)c2csc(-c3cccc(Cl)c3Cl)n2)C1

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 11/20 0.67
TLR7 Q9NYK1 1/20 0.46
PANK3 Q9H999 1/20 0.46
TRPC3 Q13507 1/20 0.42
TRPC6 Q9Y210 1/20 0.42
KDM5B Q9UGL1 1/20 0.40
CCNK O75909 1/20 0.40
CDK12 Q9NYV4 1/20 0.40
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HSD11B1 P28845 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3537831 0.80 HTR2C (0.72) HTR2CTLR7PANK3TRPC3TRPC6
SCHEMBL22522958 0.80 HTR2C (0.52) HTR2CTLR7PANK3
SCHEMBL3543127 0.80 HTR2C (0.72) HTR2CTLR7PANK3TRPC3TRPC6
SCHEMBL4972803 0.79 HTR2C (0.73) HTR2CTLR7PANK3TRPC3TRPC6
SCHEMBL22494622 0.78 HTR2C (0.50) HTR2CTLR7TRPC3TRPC6NPC1
SCHEMBL3537862 0.77 HTR2C (1.00) HTR2CTLR7PANK3NPC1ALDH1A1
SCHEMBL3537336 0.77 HTR2C (1.00) HTR2CTLR7PANK3NPC1ALDH1A1
SCHEMBL3537727 0.76 HTR2C (0.80) HTR2CTLR7PANK3TRPC3TRPC6
SCHEMBL4974911 0.76 HTR2C (0.64) HTR2CTLR7PANK3HSD11B1
SCHEMBL4972147 0.75 HTR2C (0.68) HTR2CTLR7PANK3TRPC3TRPC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3692028-B1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS INC (US) 2023-04-26 EP claimed
US-20220185806-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS, INC. 2022-06-16 US claimed
EP-3692028-B1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS INC (US) 2023-04-26 EP disclosed
US-20220204495-A1 INHIBITING TRABID Valo Health, LLC 2022-06-30 US disclosed
US-20220185806-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS, INC. 2022-06-16 US disclosed
US-20220185806-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS, INC. 2022-06-16 US disclosed
US-11247987-B2 Inhibiting ubiquitin specific peptidase 30 FORMA THERAPEUTICS, INC. (US) 2022-02-15 US disclosed
US-11247987-B2 Inhibiting ubiquitin specific peptidase 30 FORMA THERAPEUTICS, INC. (US) 2022-02-15 US disclosed
US-20200317658-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS, INC. 2020-10-08 US disclosed
US-20200317658-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS, INC. 2020-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220185806-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 USP30, UCHL1, UCHL3 HTR2C 4293/4885TLR7 4780/4885PANK3 4172/4885
US-11247987-B2 Inhibiting ubiquitin specific peptidase 30 USP30, UCHL1, UCHL3 HTR2C 4172/4885TLR7 4726/4885PANK3 4594/4885
US-20200317658-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 USP30, UCHL1, UCHL3 HTR2C 4293/4885TLR7 4780/4885PANK3 4172/4885
US-20220204495-A1 INHIBITING TRABID TPO, PRKACG, NFKBIA HTR2C 4278/4885TLR7 3481/4885PANK3 3590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.